Voice your opinion on congressional bill S4446-117 and let lawmakers know your stance with UnPac!

Main Subject: Health

Modernizing the Accelerated Approval Pathway Act of 2022

This bill modifies provisions relating to the accelerated approval of drugs for serious or life-threatening diseases or conditions, including by requiring the Food and Drug Administration (FDA) to publish its reasons when it determines a postapproval study to be unnecessary. The bill also establishes a pilot program and an FDA council to support the development of drugs for rare diseases and ensure the appropriate use of the accelerated approval pathway, respectively.

Senate Actions

IntroReferral
Jun. 22 2022	Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S3077-3078)

Library of Congress Actions

IntroReferral
Jun. 22 2022	Introduced in Senate

Senate bill S4446-117

A bill to modernize the process of accelerated approval of a drug for a serious or life-threatening disease or condition.

Senate bill S4446-117

A bill to modernize the process of accelerated approval of a drug for a serious or life-threatening disease or condition.

Promote the cause!

Or use this QR code